QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 abbvie-to-present-new-data-from-antibody-drug-conjugate-adc-platform-at-esmo-congress-2024-highlighting-mirvetuximab-soravtansine-for-ovarian-cancer-telisotuzumab-vedotin-and-adizutecan-for-non-small-cell-lung-and-gastroesophageal-cancers

Full data from the primary analysis of the positive, single-arm Phase 2 PICCOLO trial, evaluating mirvetuximab soravtansine (EL...

 psychedelic-drugs-market-set-to-grow-by-137b-by-2028-driven-by-mental-health-disorders-and-ai-integration

The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI adva...

 abbvie-announces-vraylar-receives-reimbursement-recommendation-from-canadas-drug-agency-for-treatment-of-schizophrenia-in-adults-following-successful-negotiations-and-loi

VRAYLAR, an atypical antipsychotic medication, received its Notice of Compliance from Health Canada on April 22, 2022.Following...

 as-regulators-gear-up-to-decide-on-bristol-myers-schizophrenia-treatment-neurocrine-biosciences-data-disappoints-investors

Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms,...

 regulators-expected-to-approve-innovative-schizophrenia-treatment-from-bristol-myers-karuna

Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomb...

 novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets

Analysts expect Novo Nordisk's Ozempic and other major drugs to be included in 2027 Medicare price negotiations. Despite co...

 piper-sandler-maintains-overweight-on-abbvie-raises-price-target-to-209

Piper Sandler analyst Christopher Raymond maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $1...

Core News & Articles

TEPKINLY is the first and only subcutaneous bispecific antibody approved as a monotherapy in the European Union to treat both r...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION